Company profile: Cassava Sciences
1.1 - Company Overview
Company description
- Provider of an investigational oral drug, Simufilam, for Alzheimer’s disease that stabilizes altered filamin A in the brain; currently in Phase III trials. Offers clinical trial programs (rethinkALZ and refocusALZ) to evaluate efficacy and safety of Simufilam, and an Expanded Access program for patients not eligible for trials with serious or life-threatening conditions.
Products and services
- Simufilam: An oral drug in Phase III clinical trials aimed at treating Alzheimer’s disease by stabilizing altered filamin A protein in the brain
- RefocusALZ: A clinical trial program designed to assess the impact of Simufilam on Alzheimer’s disease patients
- RethinkALZ: A clinical trial program focused on evaluating the efficacy and safety of Simufilam in patients with Alzheimer’s disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cassava Sciences
Vallon Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development focused on new medications for central nervous system disorders, including ADAIR, an investigational novel abuse-deterrent formulation of amphetamine immediate release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vallon Pharmaceuticals company profile →
Adapt Pharma
HQ: United States
Website
- Description: Provider of therapeutic treatments for patients with special medical conditions, including NARCAN (naloxone hydrochloride) Nasal Spray, an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adapt Pharma company profile →
Alcyone Therapeutics
HQ: United States
Website
- Description: Provider of precision CNS genetic therapies and delivery technologies, including Falcon Precision Delivery System for precise intra-CSF drug delivery; ThecaFlex DRx System, an implantable system for direct intrathecal CSF access designed for safer, long-term drug administration; ACTX-101 gene therapy for Rett syndrome using X-reactivation; and miREX to reactivate silenced healthy X chromosomes for X-linked dominant mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alcyone Therapeutics company profile →
Satsuma Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satsuma Pharmaceuticals company profile →
Compass Pathways
HQ: United Kingdom
Website
- Description: Provider of psilocybin-based mental health therapies and research for treatment-resistant depression, PTSD, and anorexia nervosa. Offers COMP360 psilocybin treatment administered with psychological support, a therapist training programme, a Discovery Center for preclinical studies, and support for investigator-initiated studies, conducting clinical trials and research on psilocybin therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compass Pathways company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cassava Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cassava Sciences
2.2 - Growth funds investing in similar companies to Cassava Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cassava Sciences
4.2 - Public trading comparable groups for Cassava Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →